267 related articles for article (PubMed ID: 20093809)
21. Non-erythropoietic tissue-protective peptides derived from erythropoietin: WO2009094172.
Dumont F; Bischoff P
Expert Opin Ther Pat; 2010 May; 20(5):715-23. PubMed ID: 20192905
[TBL] [Abstract][Full Text] [Related]
22. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside.
Lipsic E; Schoemaker RG; van der Meer P; Voors AA; van Veldhuisen DJ; van Gilst WH
J Am Coll Cardiol; 2006 Dec; 48(11):2161-7. PubMed ID: 17161240
[TBL] [Abstract][Full Text] [Related]
23. Selective modulation of the erythropoietic and tissue-protective effects of erythropoietin: time to reach the full therapeutic potential of erythropoietin.
Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
Biochim Biophys Acta; 2007 Sep; 1776(1):1-9. PubMed ID: 17683868
[TBL] [Abstract][Full Text] [Related]
24. Localization of an essential ligand binding determinant of the human erythropoietin receptor to a domain N-terminal to the WSXWS motif: implications for soluble receptor function.
Schimmenti LA; Blechert G; Harris KW; Winkelmann JC
Exp Hematol; 1995 Dec; 23(13):1341-6. PubMed ID: 7498361
[TBL] [Abstract][Full Text] [Related]
25. Modulation of cellular stress response via the erythropoietin/CD131 heteroreceptor complex in mouse mesenchymal-derived cells.
Bohr S; Patel SJ; Vasko R; Shen K; Iracheta-Vellve A; Lee J; Bale SS; Chakraborty N; Brines M; Cerami A; Berthiaume F; Yarmush ML
J Mol Med (Berl); 2015 Feb; 93(2):199-210. PubMed ID: 25373867
[TBL] [Abstract][Full Text] [Related]
26. Erythropoietin: a hormone with multiple functions.
Lombardero M; Kovacs K; Scheithauer BW
Pathobiology; 2011; 78(1):41-53. PubMed ID: 21474975
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin as a tissue-protective cytokine in brain injury: what do we know and where do we go?
Grasso G; Sfacteria A; Cerami A; Brines M
Neuroscientist; 2004 Apr; 10(2):93-8. PubMed ID: 15070483
[TBL] [Abstract][Full Text] [Related]
28. [Erythropoietin--a new therapy in cerebral ischemia?].
Kalialis LV; Olsen NV
Ugeskr Laeger; 2003 Jun; 165(24):2477-81. PubMed ID: 12872467
[TBL] [Abstract][Full Text] [Related]
29. Systemic inflammatory response to exhaustive exercise. Cytokine kinetics.
Suzuki K; Nakaji S; Yamada M; Totsuka M; Sato K; Sugawara K
Exerc Immunol Rev; 2002; 8():6-48. PubMed ID: 12690937
[TBL] [Abstract][Full Text] [Related]
30. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
31. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human erythropoietin prevents lipopolysaccharide-induced vascular hyporeactivity in the rat.
di Villa Bianca Rd; Sorrentino R; Mitidieri E; Marzocco S; Autore G; Thiemermann C; Pinto A; Sorrentino R
Shock; 2009 May; 31(5):529-34. PubMed ID: 18838949
[TBL] [Abstract][Full Text] [Related]
33. Erythropoietin augments the cytokine response to acute endotoxin-induced inflammation in humans.
Hojman P; Taudorf S; Lundby C; Pedersen BK
Cytokine; 2009 Mar; 45(3):154-7. PubMed ID: 19167238
[TBL] [Abstract][Full Text] [Related]
34. HGF activates signal transduction from EPO receptor on human cord blood CD34+/CD45+ cells.
Iguchi T; Sogo S; Hisha H; Taketani S; Adachi Y; Miyazaki R; Ogata H; Masuda S; Sasaki R; Ito M; Fukuhara S; Ikehara S
Stem Cells; 1999; 17(2):82-91. PubMed ID: 10195568
[TBL] [Abstract][Full Text] [Related]
35. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
Mannello F; Tonti GA
Oncologist; 2008 Jul; 13(7):761-8. PubMed ID: 18596367
[TBL] [Abstract][Full Text] [Related]
36. Erythropoietin attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain.
Kumral A; Baskin H; Yesilirmak DC; Ergur BU; Aykan S; Genc S; Genc K; Yilmaz O; Tugyan K; Giray O; Duman N; Ozkan H
Neonatology; 2007; 92(4):269-78. PubMed ID: 17627093
[TBL] [Abstract][Full Text] [Related]
37. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism.
Xu X; Cao Z; Cao B; Li J; Guo L; Que L; Ha T; Chen Q; Li C; Li Y
Surgery; 2009 Sep; 146(3):506-14. PubMed ID: 19715808
[TBL] [Abstract][Full Text] [Related]
38. Down-modulation of high-affinity receptors for erythropoietin on murine erythroblasts by interleukin 3.
Fraser JK; Nicholls J; Coffey C; Lin FK; Berridge MV
Exp Hematol; 1988 Oct; 16(9):769-73. PubMed ID: 2844574
[TBL] [Abstract][Full Text] [Related]
39. Activation of the β-common receptor by erythropoietin impairs acetylcholine-mediated vasodilation in mouse mesenteric arterioles.
Kilar CR; Diao Y; Sautina L; Sekharan S; Keinan S; Carpino B; Conrad KP; Mohandas R; Segal MS
Physiol Rep; 2018 Jun; 6(12):e13751. PubMed ID: 29939494
[TBL] [Abstract][Full Text] [Related]
40. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.
Brines M; Patel NS; Villa P; Brines C; Mennini T; De Paola M; Erbayraktar Z; Erbayraktar S; Sepodes B; Thiemermann C; Ghezzi P; Yamin M; Hand CC; Xie QW; Coleman T; Cerami A
Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10925-30. PubMed ID: 18676614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
